Events:
There were 17 events in the standard therapy group (15 relapses, and 2 treatment related death due to liver failure and sepsis), while patients treated in the augmented therapy group had 6 events (one died of second cancer/ AML, 2 relapsed, and 3 had refractory disease). The median time to relapse for all patients was 13.8 months (range, 6-55 months). Eleven of 17 patients who relapsed (65%) had isolated BM relapse, 4 had isolated extramedullary relapse, and 2 had combined relapse (BM+CNS). Six patients (35%) achieved CR2 after salvage chemotherapy, of them three patients underwent allogenic -HCT in CR2, only one patient alive in continuous complete remission (CCR) post-transplant; all others (N=5) succumbed due to second relapses.